90
Participants
Start Date
August 5, 2022
Primary Completion Date
August 18, 2023
Study Completion Date
August 18, 2023
Hemay005
Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi’an
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing
Jilin Provincial People's Hospital, Changchun
The First Affiliated Hospital of Bengbu Medical University, Hefei
Pingxiang people's Hospital, Pingxiang
Chenzhou first people's Hospital, Chenzhou
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan
Puyang Oilfield General Hospital, Puyang
Guangdong Provincial People's Hospital, Guangzhou
The Third Affiliated Hospital of Sun Yat sen University, Guangzhou
Hebei CNPC Central Hospital, Langfang
Tianjin Hemay Pharmaceutical Co., Ltd
INDUSTRY